2024
Real-World Experience and Outcomes With Percutaneous Coronary Intervention for Protected Versus Unprotected Left Main Coronary Artery Disease: Insights from the Veteran Affairs Clinical Assessment Reporting and Tracking Program
Gonzalez P, Hebbe A, Hussain Y, Khera R, Banerjee S, Plomondon M, Waldo S, Pfau S, Curtis J, Shah S. Real-World Experience and Outcomes With Percutaneous Coronary Intervention for Protected Versus Unprotected Left Main Coronary Artery Disease: Insights from the Veteran Affairs Clinical Assessment Reporting and Tracking Program. The American Journal Of Cardiology 2024, 222: 39-50. PMID: 38677666, DOI: 10.1016/j.amjcard.2024.04.039.Peer-Reviewed Original ResearchULM percutaneous coronary interventionPercutaneous coronary interventionPropensity-matched cohortMyocardial infarctionCoronary interventionAll-cause mortalityTracking programUS clinical practiceOne-year MACEOne-year outcomesIncidence of rehospitalizationAdverse cardiovascular eventsUnprotected left main coronary artery diseaseAcute coronary syndromeCoronary artery diseaseRates of MIMechanical circulatory supportLeft main percutaneous coronary interventionPCI patientsUrgent revascularizationPractice patternsCart programLeft main bifurcationPrimary outcomeMatched cohort
2023
Antiplatelet Strategies Following PCI: A Review of Trials Informing Current and Future Therapies
Thomas A, Gitto M, Shah S, Saito Y, Tirziu D, Chieffo A, Stefanini G, Lansky A. Antiplatelet Strategies Following PCI: A Review of Trials Informing Current and Future Therapies. Journal Of The Society For Cardiovascular Angiography & Interventions 2023, 2: 100607. PMID: 39130709, PMCID: PMC11307978, DOI: 10.1016/j.jscai.2023.100607.Peer-Reviewed Original ResearchDual antiplatelet therapyAntiplatelet regimensPatient-specific risk profileShorter DAPT durationDuration of therapyPercutaneous coronary interventionDAPT strategyIschemic riskAntiplatelet therapyDAPT durationAntiplatelet strategiesCoronary interventionOngoing trialsMajor trialsRecent trialsPractice guidelinesFuture therapiesRisk profileTherapyStent technologyTrialsRegimensNumber of trialsSignificant reductionSignificant changes